SCYNEXIS Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
SCYNEXIS has a total shareholder equity of $60.4M and total debt of $12.8M, which brings its debt-to-equity ratio to 21.2%. Its total assets and total liabilities are $107.8M and $47.4M respectively.
Anahtar bilgiler
21.2%
Borç/özkaynak oranı
US$12.78m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$73.04m |
| Eşitlik | US$60.41m |
| Toplam yükümlülükler | US$47.40m |
| Toplam varlıklar | US$107.81m |
Son finansal sağlık güncellemeleri
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Recent updates
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop
Jun 19SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 12SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: SCYX's short term assets ($94.6M) exceed its short term liabilities ($25.2M).
Uzun Vadeli Yükümlülükler: SCYX's short term assets ($94.6M) exceed its long term liabilities ($22.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: SCYX has more cash than its total debt.
Borcun Azaltılması: SCYX's debt to equity ratio has reduced from 74.3% to 21.2% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: SCYX has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if SCYX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.